2023 World Conference on Lung Cancer (Posters)-P2.18. Impact of Inclusion of Immunotherapy in National Treatment Guidelines on Survival Outcomes in Malignant Pleural Mesothelioma

P2.18. Impact of Inclusion of Immunotherapy in National Treatment Guidelines on Survival Outcomes in Malignant Pleural Mesothelioma - PDF(Slides)

Back to course

Pdf Summary

This study explores the impact of the inclusion of immunotherapy in national treatment guidelines on survival outcomes in malignant pleural mesothelioma (MPM). The annual incidence of MPM has remained stable in the United States, and although there have been treatment advances, the impact of immunotherapy on real-world MPM survival outcomes needs to be evaluated further.<br /><br />The researchers identified all MPM patients diagnosed between 2004 and 2019 in the National Cancer Database (NCDB). They assessed the differences in demographic, disease, and treatment characteristics by year of diagnosis. They also analyzed the effect of histology, stage at diagnosis, and various treatments including surgery, radiation, chemotherapy, and immunotherapy on overall survival (OS).<br /><br />The results showed that the introduction of immunotherapy as a second-line treatment in the National Comprehensive Cancer Network (NCCN) guidelines in 2017 led to a notable increase in the number of MPM patients treated with immunotherapy. Overall survival for all patients treated with immunotherapy was 17.28 months, consistent with survival data from previous pivotal trials.<br /><br />The study also found that immunotherapy had a positive impact on overall survival across different histologies, with an increase of 5-7 months. Furthermore, the analysis demonstrated that immunotherapy increased overall survival by 6 months across the time periods studied (2004-2012 and 2013-2019).<br /><br />These findings suggest that immunotherapy has revolutionized the treatment of MPM and has the potential to improve survival outcomes. However, further research is needed to examine the long-term impact of immunotherapy and identify the specific demographic groups that may benefit the most from this treatment.<br /><br />In conclusion, the inclusion of immunotherapy in national treatment guidelines has led to an increase in the number of MPM patients treated with this therapy. Immunotherapy has demonstrated improved overall survival in MPM patients, and its impact across different histologies and time periods suggests its potential as a valuable treatment option.

Asset Subtitle

Logan Roof

Meta Tag

Speaker Logan Roof

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical

Keywords

immunotherapy

national treatment guidelines

survival outcomes

malignant pleural mesothelioma

MPM

National Cancer Database

overall survival

pivotal trials

positive impact

treatment option